Machine signal
Active cluster sell — 5 distinct insiders, $5.8M, window ends Nov 16, 2026.
Figures computed from official regulatory filings — .
Analysttarget 59.22 USD (+53%) · consensus 4.9/5 · 10 buy · 0 hold · 0 sell
Ownershipinsiders 3.22% · institutions 100.77% · short 13.3% of float · 9.05d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Septerna, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Market information source · Nov 16, 2026
SEC company identity · Nov 16, 2026
Purchases and sales · full history
19 buys44 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Labrucherie Gil Mtrack record | Sell | $30.1K | SEC | ||
| Labrucherie Gil Mtrack record | Sell | $146.3K | SEC | ||
| Labrucherie Gil Mtrack record | Sell | $655.9K | SEC | ||
| Finer Jeffrey | Sell | $91.3K | SEC | ||
| Finer Jeffrey | Sell | $228.4K | SEC | ||
| Finer Jeffrey | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Finer Jeffrey | Sell | $127.8K | SEC | ||
| Finer Jeffrey | Sell | $123.8K | SEC | ||
| Finer Jeffrey | Exercise | $51.1K | SEC | ||
| Finer Jeffrey | Sell | $235.7K | SEC | ||
| Ezekowitz Alan | Sell | $620.6K | SEC | ||
| Ezekowitz Alan | Sell | $207.3K | SEC | ||
| Ezekowitz Alan | Sell | $54.8K | SEC | ||
| Ezekowitz Alan | Sell | $102.5K | SEC | ||
| Ezekowitz Alan | Sell | $319.2K | SEC | ||
| Ezekowitz Alan | Sell | $1.1M | SEC | ||
| Ezekowitz Alan | Sell | $1.5M | SEC | ||
| Bhatt Elizabeth | Exercise | $27.2K | SEC | ||
| Bhatt Elizabeth | Sell | $109.3K | SEC | ||
| Bhatt Elizabeth | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Bhatt Elizabeth | Sell | $40.3K | SEC | ||
| Patni Rajiv | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Long Daniel D. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Long Daniel D. | Sell | $126.1K | SEC | ||
| Long Daniel D. | Exercise | $9.2K | SEC |